156 related articles for article (PubMed ID: 8996120)
21. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
Weaver CH; Petersen FB; Appelbaum FR; Bensinger WI; Press O; Martin P; Sandmaier B; Deeg HJ; Hansen JA; Brunvand M
J Clin Oncol; 1994 Dec; 12(12):2559-66. PubMed ID: 7989929
[TBL] [Abstract][Full Text] [Related]
22. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
[TBL] [Abstract][Full Text] [Related]
23. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
[TBL] [Abstract][Full Text] [Related]
26. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.
Vose JM; Rizzo DJ; Tao-Wu J; Armitage JO; Bashey A; Burns LJ; Christiansen NP; Freytes CO; Gale RP; Gibson J; Giralt SA; Herzig RH; Lemaistre CF; McCarthy PL; Nimer SD; Petersen FB; Schenkein DP; Wiernik PH; Wiley JM; Loberiza FR; Lazarus HM; van Biesen K; Horowitz MM
Biol Blood Marrow Transplant; 2004 Feb; 10(2):116-27. PubMed ID: 14750077
[TBL] [Abstract][Full Text] [Related]
27. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.
Vose JM; Anderson JR; Kessinger A; Bierman PJ; Coccia P; Reed EC; Gordon B; Armitage JO
J Clin Oncol; 1993 Oct; 11(10):1846-51. PubMed ID: 8105034
[TBL] [Abstract][Full Text] [Related]
28. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
29. [Autologous bone marrow transfusion in the treatment of adults with hematologic neoplasms. Experiences from Bern].
Brun del Re GP; Tschopp L; Cerny T; Bucher U
Schweiz Med Wochenschr; 1989 Jun; 119(25):902-10. PubMed ID: 2667130
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Stone RM; Neuberg D; Soiffer R; Takvorian T; Whelan M; Rabinowe SN; Aster JC; Leavitt P; Mauch P; Freedman AS
J Clin Oncol; 1994 Dec; 12(12):2535-42. PubMed ID: 7989927
[TBL] [Abstract][Full Text] [Related]
31. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[TBL] [Abstract][Full Text] [Related]
32. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of curative effect of autologous peripheral blood stem cell transplantation versus bone marrow transplantation for acute leukemia].
Zhang YZ; Zhang BL; Yao SQ; Liu HC; Lou FD; Gao CJ; Han XP; Wu XX; Zhao Y; Wang QS; Jing Y; Zhang M; Jin HJ; Shi ZJ; Da WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):81-5. PubMed ID: 12667296
[TBL] [Abstract][Full Text] [Related]
34. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
[TBL] [Abstract][Full Text] [Related]
35. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
36. [Autologous bone marrow transplantation in children with acute leukemia or non-Hodgkin's lymphoma].
Emminger W; Hinterberger W; Emminger-Schmidmeier W; Peters C; Fink FM; Zoubek A; Haas OA; Höcker P; Hawliczek R; Knapp W
Wien Med Wochenschr; 1991; 141(9-10):225-8. PubMed ID: 1683071
[TBL] [Abstract][Full Text] [Related]
37. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen.
Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J
Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724
[TBL] [Abstract][Full Text] [Related]
38. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
40. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]